Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
84.35 EUR | +0.30% | -2.10% | -11.60% |
12:46pm | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
17/05 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Sales 2024 * | 279.97Cr 304.04Cr 25TCr | Sales 2025 * | 276.55Cr 300.32Cr 25TCr | Capitalization | 2.05TCr 2.23TCr 1,86000Cr |
---|---|---|---|---|---|
Net income 2024 * | -42Cr -45Cr -3.76TCr | Net income 2025 * | -49Cr -53Cr -4.45TCr | EV / Sales 2024 * | 2.06 x |
Net cash position 2024 * | 1.48TCr 1.6TCr 1,33800Cr | Net cash position 2025 * | 1.38TCr 1.49TCr 1,24600Cr | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
-49
x | P/E ratio 2025 * |
-43.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.48% |
Latest transcript on BioNTech SE
1 week | -2.10% | ||
Current month | +1.26% | ||
1 month | +2.56% | ||
3 months | -0.47% | ||
6 months | -6.82% | ||
Current year | -11.60% |
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02/08/02 |
Özlem Türeci
FOU | Founder | 57 | 02/08/02 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 69 | 01/22/01 |
Director/Board Member | 67 | 02/08/02 | |
Helmut Jeggle
CHM | Chairman | 53 | 02/08/02 |
Date | Price | Change |
---|---|---|
21/24/21 | 84.35 | +0.30% |
20/24/20 | 84.1 | +0.90% |
17/24/17 | 83.35 | -2.51% |
16/24/16 | 85.5 | +1.00% |
15/24/15 | 84.65 | -0.41% |
Real-time BOERSE MUENCHEN, May 21, 2024 at 06:01 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.58% | 12TCr | |
+12.41% | 11TCr | |
-3.32% | 2.16TCr | |
-3.35% | 1.82TCr | |
-38.57% | 1.76TCr | |
+7.51% | 1.43TCr | |
+35.67% | 1.24TCr | |
-24.50% | 828.11Cr | |
+20.91% | 826.08Cr |
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock